Scarica l'app Stockscreener
1.385
1.43%
-0.015
Precedente Chiudi:
$1.40
Aprire:
$1.35
Volume 24 ore:
85,205
Relative Volume:
0.55
Capitalizzazione di mercato:
$24.59M
Reddito:
-
Utile/perdita netta:
$-8.29M
Rapporto P/E:
-1.9786
EPS:
-0.7
Flusso di cassa netto:
$-6.47M
1 W Prestazione:
-1.43%
1M Prestazione:
-10.39%
6M Prestazione:
-2.82%
1 anno Prestazione:
-22.47%
Intervallo 1D:
$1.34
$1.41
Intervallo di 1 settimana:
$1.15
$1.44
Portata 52W:
$0.94
$2.55
NanoViricides Inc Stock (NNVC) Company Profile
Nome
NanoViricides Inc
Settore
Industria
Telefono
203-937-6137
Indirizzo
1 Controls Drive, Shelton, CT
Confronta NNVC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.3835 | 24.59M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.92 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.47 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.93 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
550.40 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.15 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2015-02-11 | Iniziato | Midtown Partners | Strong Buy |
NanoViricides Inc Borsa (NNVC) Ultime notizie
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan - Knoxville News Sentinel
NanoViricides' NV-387 Emerges as a Promising Broad-Spectrum Antiviral Against COVID-19 and Bird Flu - citybuzz -
Small cap wrap: Fineqia, NanoViricides, Standard Uranium... - Proactive Investors
NanoViricides touts antiviral NV-387 as tool against new COVID variant - Proactive financial news
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in AfricaPhase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu - The Columbus Dispatch
NanoViricides Advances Measles Drug Program as Global Outbreaks Rise - citybuzz -
NanoViricides Measles Drug Development Animal Study is Imminent - Akron Beacon Journal
Small cap wrap: NanoViricides, New Era Helium, Charbone Hydrogen, Voyageur Pharmaceuticals... - Proactive Investors
NanoViricides commissions animal study of broad-spectrum antiviral for measles - Proactive Investors
NanoViricides (NNVC) Advances Measles Drug Development | NNVC St - GuruFocus
Breakthrough Measles Drug Enters Critical Testing Phase as Global Cases Surge 10X - Stock Titan
Nanoviricides (NNVC) To Unveil 'Escape-Proof' Antiviral Platform At Major Biotech Convention - MENAFN.com
NanoViricides (NNVC) to Unveil 'Escape-Proof' Antiviral Platform at Major Biotech Convention - openPR.com
Gold Is Bullish, But Be Aware Of Deeper Intraday Pullback; Elliott Wave Intraday Analysis - The Globe and Mail
NanoViricides (NNVC) to Unveil ‘Escape-Proof’ Antiviral Platform at Major Biotech Convention - The Globe and Mail
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 - Lohud
NanoViricides to Showcase Breakthrough Antiviral Platform at BIO International Convention - citybuzz -
Hudbay Receives TSX Approval for Normal Course Issuer Bid - The Globe and Mail
NanoViricides to present at BIO International Convention 2025 in Boston - Proactive financial news
NanoViricides president backs FDA's targeted COVID booster policy shift - Proactive financial news
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan - ACCESS Newswire
Small cap wrap: NanoViricides, Trust Stamp, NextSource, StickIt... - Proactive financial news
NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox - Proactive Investors
NanoViricides: MPox ethics approval enables Phase 2 application - Proactive Investors
NanoViricides: Fiscal Q3 Earnings Snapshot - Huron Daily Tribune
Small cap wrap: atai, Black Swan Graphene, TNR Gold, NanoViricides... - Proactive financial news
NanoViricides progresses antiviral portfolio as measles and MPox threats rise - Proactive financial news
Measles Cases Are Increasing Globally; MPox Continues to Be a ThreatBroad-Spectrum Antiviral Drug Could Be the Solution - The Derrick
AMAT Likely to Beat Q2 Earnings Estimates: How to Play the Stock - The Globe and Mail
Small cap wrap: NanoViricides, Alvopetro, Polarean... - Proactive financial news
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC - Proactive financial news
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo - The Derrick
Renaissance Technologies LLC Buys 30,800 Shares of NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides Inc Azioni (NNVC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.04%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):